Regulations of the key mediators in inflammation and atherosclerosis by Aspirin in human macrophages

Lipids in Health and Disease

Volumn 9, Issue , 2010, Pages

  Lu, Li ^a   Liu, Hong ^a   Peng, Jiahe ^a   Gan, Lin ^a   Shen, Lili ^a   Zhang, Qian ^a   Li, Liangpeng ^a   Zhang, Li ^a   Su, Chang ^a   Jiang, Yu ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER A1; ACETYLSALICYLIC ACID; GELATINASE B; MESSENGER RNA; SCAVENGER RECEPTOR BI; TRANSCRIPTION FACTOR RELA; ABC TRANSPORTER; CD36 ANTIGEN; CHOLESTEROL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NONSTEROID ANTIINFLAMMATORY AGENT;

ARTICLE; ATHEROSCLEROSIS; CELL ACTIVITY; CELL STIMULATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; DRUG MECHANISM; EFFUSION; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; INFLAMMATION; MACROPHAGE; PROTEIN EXPRESSION; REGULATORY MECHANISM; SUPERNATANT; ANIMAL; GENE EXPRESSION REGULATION; METABOLISM; MOUSE;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIGENS, CD36; ASPIRIN; ATHEROSCLEROSIS; ATP-BINDING CASSETTE TRANSPORTERS; CHOLESTEROL; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION; MACROPHAGES; MATRIX METALLOPROTEINASE 9; MICE; NF-KAPPA B;

EID: 77950405789     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/1476-511X-9-16     Document Type: Article

References (23)

1. North of England evidence based guideline development project: guideline on the use of aspirin as secondary prophylaxis for vascular disease in primary care. M Eccles N Freemantle J Mason, Br Med J 1998 316 1303 9 (Pubitemid 28181941)
2. Collaborative meta-analysis of randomized trials of antiplatelet theraphy for prevention of death, myocardial infarction, and stroke in high risk patients. Antithrombotic Trialists' Collaboration, Br Med J 2002 324 71 86 10.1136/bmj.324.7329.71
3. Aspirin for the primary prevention of cardiovascular evnets: a summary of the evidence for the U.S. Preventative Services Task Force. M Hayden M Pignone C Phillips C Mulrow, Ann Intern Med 2002 136 161 72 11790072 (Pubitemid 34073943)
4. Inflammation in atherosclerosis. P Libby, Nature 2002 420 6917 864 74 10.1038/nature01323 (Pubitemid 36019640)
5. Atherosclerosis. AJ Lusis, Nature 2000 407 233 41 10.1038/35025203 11001066
6. Pathophysiology of coronary thrombosis: role of plaque rupture and plaque erosion. PK Shah, Prog Cardiovasc Dis 2002 44 357 68 10.1053/pcad.2002.123473 12024334
7. Overexpression of COX-2, Prostaglandin E Synthase-1 and Prostaglandin E Receptors in blood mononuclear cells and plaque of patients with carotid atherosclerosis: Regulation by nuclear factor-B. GH Almudena MV Jose SG Eva, et al. Atherosclerosis 2006 187 139 149 10.1016/j.atherosclerosis.2005.08.035 16212965
8. Overexpression of functionally coupled cyclooxygenase-2 and prostaglandin E synthase in symptomatic atherosclerotic plaques as a basic of prostaglandin E(2)-dependent plaque instability. F Cipollone C Prontera B Pini, et al. Circulation 2001 104 921 7 10.1161/hc3401.093152 11514380 (Pubitemid 32778044)
9. Effect of low-dose aspirin on vascular inflammation, plaque stability, and atherogenesis in low density lipoprotein receptor-deficient mice. T Cycus S Sung L Zhao, et al. Circulation 2002 106 1282 7 10.1161/01.CIR.0000027816.54430. 96 12208806
10. Stabilization of advanced atherosclerosis in low-density lipoprotein receptor-deficient mice by aspirin. T Cyrus YM Yao LX Tung, et al. Atherosclerosis 2006 184 8 14 10.1016/j.atherosclerosis.2004.10.047 16326168 (Pubitemid 41721063)
11. Cyclic AMP-specific phosphodiesterase inhibitors promote ABCA1 expression and cholesterol efflux. Lin Guorong KE Bornfeldt, Biochem Biophys Res Commun 2002 290 2 663 669 10.1006/bbrc.2001.6259 11785950
12. Inhibition of intimal hyperplasia after balloon injury in rat carotid artery model using cis-element 'decoy' of nuclear factor-kappaB binding site as a novel molecular strategy. S Yoshimura R Morishita K Hayashi K Yamamoto H Nakagami Y Kaneda N Sakai T Ogihara, Gene Ther 2001 8 21 1635 42 10.1038/sj.gt.3301566 11895002 (Pubitemid 33085585)
13. Cyclooxygenase inhibitors retard murine mammary tumor progression by reducing tumor cell migration, invasiveness and angiogenesis. JG Rozic C Chakraborty PK Lala, et al. Int J Cancer 2001 93 497 506 10.1002/ijc.1376 11477553 (Pubitemid 32701408)
14. Macrophage migration inhibitory factor induces MMP-9 expression: implication for destabilization of human atherosclerotic plaques. YZ Kong X Yu JJ Tang, et al. Atherosclerosis 2005 178 1 207 15 10.1016/j.atherosclerosis. 2004.08.030 15585220 (Pubitemid 39600835)
15. Increased expression of membrane type 3-matrix metalloproteinase in human atherosclerotic plaque: role of activated macrophages and inflammatory cytokines. H Uzui A Harpf M Liu, et al. Circulation 2002 106 3024 30 10.1161/01.CIR.0000041433.94868.12 12473546 (Pubitemid 35440283)
16. Enhanced expression of vascular matrix metalloproteinases induced in vitro by cytokines and in regions of human atherosclerotic lesions. ZS Galis M Muszynski GK Sukhova E Simon-morrissey P Libby, Ann N Y Acad Sci 1995 748 501 7 7695193
17. Oxidized low-density lipoprotein regulates matrix metalloproteinase-9 and its tissue inhibitor in human monocyte-derived macrophages. XP Xu SR Meisel JM Ong, et al. Circulation 1999 99 993 8 10051290
18. Aspirin inhibits tumor cell invasiveness induced by epstein-barr virus latent membrane protein 1 through suppression of matrix metalloproteinase-9 expression. M Shigeyuki Y Tomokazu S Hiroshi, et al. Cancer Research 2000 60 255 56
19. Aspirin increases CD36, SR-BI, and ABCA1 expression in human THP-1 macrophages. M Vĩals I Bermdez G Llaverias, et al. Cardiovasc Res 2005 66 1 141 9 10.1016/j.cardiores.2004.12.024 15769457 (Pubitemid 40357877)
20. Consequences of cellular cholesterol accumulation: basic concepts and physiological implications. I Tabas, J Clin Invest 2002 110 905 911 12370266
21. Regulation of plasma high-density lipoprotein levels by the ABCA1 transporter and the emerging role of high-density lipoprotein in the treatment of cardiovascular disease. HB Brewer AT Remaley EB Neufeld, et al. Aeterioscler Thromb Vasc Biol 2004 24 1755 1760 10.1161/01.ATV.0000142804.27420.5b (Pubitemid 39350289)
22. Importance of different pathways of cellular cholesterol efflux. PG Yancey AE Bortnick GK Weibel, et al. Arterioscler Thromb Vasc Biol 2003 23 712 719 10.1161/01.ATV.0000057572.97137.DD 12615688
23. HDL apolipoproteins and ABCA1: partners in the removal of excess cellular cholesterol. JF Oram, Arterioscler Thromb Vasc Biol 2003 23 720 727 10.1161/01.ATV.0000054662.44688.9A 12615680